China-based pharmaceutical firm RemeGen (HKG: 9995) announced the resignation of Mr. He Ruyi, Executive Director and core technical personnel of the company, from his posts as executive Director of the second session of the Board, member of the strategic committee of the Board, and Chief Strategy Officer of the company, due to personal career development needs. He will no longer hold any position in the company.
Background of Mr. He Ruyi
Mr. He Ruyi, born in March 1961, obtained a Bachelor’s degree in Medicine and a Master’s degree in Medicine from China Medical University in August 1983 and July 1986, respectively. In July 1999, he obtained a PhD in Internal Medicine from Howard University in the United States. He completed his residency training in Internal Medicine at Howard University Hospital in Washington DC and received his clinical and research training at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH) in Bethesda, Maryland. He was the former Chief Scientist at the Center for Drug Evaluation at the National Medical Products Administration (NMPA). He joined the NMPA in 2016, after having worked at the U.S. Food and Drug Administration (FDA) for almost two decades.-Fineline Info & Tech
